Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  NANOBIOTECHNOLOGY
A Global Strategic Business Report

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million. The major product segments analyzed are Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, and Nanotubes and Fullerenes), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 91 companies including many key and niche players worldwide such as Alnis Biosciences, Inc., American Pharmaceutical Partners, Inc., Biosante Phosphate Pharmaceuticals, Inc., Capsulution NanoScience AG, Carbon Nanotechnologies, Inc, C Sixty, Inc, Dendritic Nanotechnologies, Inc., Dendritech, Inc, Elan Pharmaceuticals, Flamel Technologies, Inc, iMedd, Inc., Nanospectra Biosciences, Inc., Nanophase Technologies Corporation, Nano-C, Inc., Nanocyl SA, Nanolab Systems Ltd, Nanosphere, Inc., Nanotherapeutics, Inc., Nanosys, Inc., PSiVida Ltd, Quantum Dot Corp, Starpharma Holdings Ltd, Sigma Aldrich Company, and Triton Biosystems, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1476  PAGES:    321
PRICE:    $3950  DATE:       June 2006
COMPANIES:  91  MARKET DATA TABLES:   111
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  NANOBIOTECHNOLOGY (Complete Report) Pages : 321   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS5$100
II. EXECUTIVE SUMMARY95$2250
  1. Industry Overview.....II-113 $900  
   A Curtain Raiser.....II-11$100
   What’s The Obsession With Size?.....II-2
Why Analysis at the Cellular Level is Important?.....II-2
1$100
   Lessons from Nature.....II-3
Where Conventional Molecular Science Falls Short Nanobio Steps In.....II-3
Conclusions.....II-3
1$100
   Dawn Breaks On Nanobiotechnology.....II-4
Demystifying the Intriguing World of Nanobiotech.....II-4
1$100
   Nanoparticles: The Foundation of Nanobiotechnology.....II-5
A Meeting Place of Medicine’s Best Solutions.....II-5
1$100
   Challenges.....II-61$100
   Nanotechnology Boom Echoes Downstream.....II-7
Honey, I Shrunk the World!.....II-7
1$100
   Nanotechnology & Biology Tie the Knot: “Two to Tango”.....II-8
Nanobiotechnology: The Next Battlefield.....II-8
1$100
   The Promise of Nanobiotechnology.....II-9
Biological Weaponries Against Diseases Come in Small Packages.....II-9
1$100
   Proffered Benefits of Nanobiotechnology.....II-101$100
   Opportunity & Beyond.....II-11
Nanobiotechnology – Will it Live Up to the Expectations?.....II-11
1$100
   The Future of Nanobiotechnology: Shape of Things to Come.....II-12
Nanobiotechnology: The Outer Limits.....II-12
Futuristics: A Rumination.....II-12
1$100
   Nanobiotechnology In the Year 2015.....II-13
Field of Nanodiagnostics.....II-13
Field of Regenerative Medicine.....II-13
Field of Targeted Drug Delivery.....II-13
1$100
  2. Market Dynamics.....II-145 $500  
   Short Market Sizzlers.....II-14
Consolidation to Speed Up in Nano-Enabled Delivery Systems Market.....II-14
1$100
   Dearth of Blockbuster Drugs in Pipeline Sparks Interest in Nanobio.....II-15
Demand for Novel Products Complements the Exuberant Outlook.....II-15
Public & Private Investment Pep Up the Market.....II-15
The Regulatory Framework Evolves with the Technology.....II-15
Nanomaterials & Nanoparticles Witness Robust Activity.....II-15
1$100
   Quantum Dot Patents Pose Legal Tangles.....II-16
Colloidal Quantum Dots Prices Poised to Scale Down in Long Run.....II-16
Miniaturized Liquid Handling Becomes Progressive.....II-16
1$100
   Unrealistic Expectations Exert Pressure On the Market.....II-17
High Material Costs Put a Spoke in the Market’s Growth.....II-17
Below Par Involvement from Pharma Biggies Limits Growth.....II-17
1$100
   Lack of De Facto Standards: A Challenge to Reckon With.....II-18
Loosely Defined Safety Standards Creates a Niggling Worry.....II-18
1$100
  3. Industry Issues, Challenges & Controversies.....II-195 $500  
   Embroilment Over Ethical Issues.....II-19
Social Relevance.....II-19
1$100
   Economic Relevance.....II-201$100
   Major Challenges Confronting the Industry.....II-21
Commercial Exploration: A Treacherous Voyage.....II-21
1$100
   Dendrimers Commercialization – An Uphill Task.....II-22
High Production Costs and Development Complexity.....II-22
Availability of Advanced Technology Alternatives.....II-22
1$100
   No Defined Framework to Judge New Product’s Safety and Efficacy.....II-23
1$100
  4. Industry Structure & Investment Patterns.....II-249 $1200  
   Industry Structure: A Quick Primer.....II-24
A Dissection of Select Segments.....II-24
Nanoparticles.....II-24
1$100
   Nanotubes and Fullerenes.....II-25
Dendrimers.....II-25
A Peek Into the Regulatory Framework.....II-25
1$100
   United States.....II-26
Europe.....II-26
What’s Grooming Nanobiotech into an Investment High Street?.....II-26
Interest Ignited by Nanotechnology.....II-26
1$100
   Tracking Investment Patterns in Nanobiotechnology.....II-27
Interest in Nanobiotechnology Spills Over.....II-27
1$100
   Patent Expiration Sends the Popularity Index Spiraling.....II-28
Drawing Significant Venture Capital Funds.....II-28
Table 1: Venture Capital Funding in Nanobiotechnology as Compared to Other Types of Nanotechnology: A Peek into Substantiating Numerics Taking the US Market as a Demonstrative Example.....II-28
1$350
   Swelling Government Grants.....II-29
The State of Public Sector Funding.....II-29
1$100
   Table 2: Nanobiotechnology Market in Select Regions (2004): Percentage Breakdown of Public Sector Funding by Country – South Korea, Taiwan, China, Australia, Canada, and Others (includes corresponding Graph/Chart).....II-30
A Closer Look at Regional Nano Efforts.....II-30
United States: Unraveling the Country’s Edge.....II-30
1$350
   Europe: Hot On the Heels of the US.....II-31
Germany.....II-31
France.....II-31
United Kingdom.....II-31
1$100
   Scandinavia.....II-32
Table 3: European Nanobiotechnology Market (2003 & 2004): Percentage Breakdown of Public Sector Funding by Leading Region/Country - European Commission, Germany, France, UK, and Others (includes corresponding Graph/Chart).....II-32
Japan: A Noteworthy Region.....II-32
1$350
  5. Nanobio’s Epochal Strides In Modern Medicine.....II-3321 $1400  
   A Primer.....II-33
Impact on Drug Delivery Systems.....II-33
1$100
   Benefits Offered.....II-34
Drug Encapsulation.....II-34
1$100
   High Level of Specificity.....II-35
Increase in Drug Solubility and Uptake.....II-35
Greater Usage Flexibility.....II-35
Impact On Molecular Diagnostic Imaging.....II-35
1$100
   Seeing The Unseen.....II-36
Impact On Pharmaceutical Drug Formulations.....II-36
1$100
   Impact On Therapeutics.....II-37
Silver Nanoparticles as Effective Antimicrobial Agents.....II-37
1$100
   Modern Day Nanomedicine: A Current Scenario.....II-38
Nanomedicine: The Cynosure of All Eyes.....II-38
1$100
   Drug Delivery Systems Epitomized by Nanomedicine.....II-391$100
   Targeted NanoDrug Delivery & Release.....II-401$100
   A Peek Into Potential Nanobio Enabled Drug Carriers.....II-41
Micelles.....II-41
Liposomes.....II-41
Dendrimers & Liquid Crystals.....II-41
Nanoparticles.....II-41
1$100
   Polymeric Nanoparticles.....II-42
Hydrogels.....II-42
Molecularly Imprinted Polymers.....II-42
Microelectromechanical Systems (MEMS).....II-42
Nanosuspensions.....II-42
1$100
   Fullerenes: A Platform for GenX Drug Delivery.....II-43
Types of Nano-Based Drug Delivery Systems, Related Materials, and
  Structures.....II-43
1$100
   Dynamics of Regenerative Medicine.....II-441$100
   Tissue Engineering and Restorations.....II-45
Nanotechnology Enabled Diagnostics.....II-45
1$100
   Promised Path Breaking Applications in Molecular Diagnostics & Imaging.....II-461$100
   In-Vitro Diagnostics.....II-47
In-Vivo Diagnostics.....II-47
1$100
   Nanoprobes & Implantable Devices in In-vivo Imaging.....II-48
Nanocomposites in Molecular Labeling & Diagnostics.....II-48
1$100
   Laboratory-on-a-Chip – A Revolutionary Technology in Biomolecular
  Detection.....II-49
Biosensors – Heralding New Opportunities in Molecular Diagnostics.....II-49
1$100
   Despite Huge Potential Key Hurdles Remain in Commercialization.....II-50
Magnetic Nanoparticles for Imaging Applications in MRI.....II-50
Dendrimers Promise Milestone Applications in MRI.....II-50
1$100
   Conclusions.....II-51
Gauging the Real World Impact of Nanobiotech On Cancer: A Case Study.....II-51
1$100
   Quantum Dots Cock a Snook at Traditional Anti-Body Labeling Agents.....II-52
Chemotherapeutic Reengineering & Gene Therapy: New Treatment Regimes.....II-52
1$100
   Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis.....II-53
1$100
  6. Technology Overview.....II-5410 $800  
   Nanotechnology: An Introduction.....II-54
A Revolution in the Making.....II-54
1$100
   Nanobiotechnology: An Exposition.....II-55
Nanobiotechnology & Medicine.....II-55
Nanobiotechnology & Biofuels.....II-55
1$100
   Global Nanobiotechnology Market (2005): Major Products.....II-56
Global Nanobiotechnology Market (2005): Major Products Under Development.....II-56
1$100
   Analysis of Major Technology Segments.....II-57
Nanomaterials.....II-57
Nanoparticles.....II-57
1$100
   Nanoparticles in Labeling or Bio Tagging.....II-58
Nanoparticles as Biomarkers.....II-58
Classification of Nanoparticles.....II-58
Solid Nanoparticles.....II-58
1$100
   Solid Lipid Nanoparticles.....II-59
Calcium Phosphate Nanoparticles.....II-59
Dendrimers.....II-59
Dendrimers as Templates for Synthesis of Hybrid Nanostructures.....II-59
1$100
   Nanocomposites.....II-60
Lamellar Nanocomposites.....II-60
Nanostructured Materials and Membranes.....II-60
1$100
   Nanotubes and Fullerenes.....II-61
Other Nanomaterials.....II-61
Nanoshells.....II-61
Nanohorns.....II-61
Nanocapsules.....II-61
1$100
   Nanodevices.....II-62
Nanotools.....II-62
Select Nanotools.....II-62
Atomic Force Microscopes.....II-62
1$100
   Hot Embossing Lithography.....II-63
Dip-Pen Nanolithography.....II-63
1$100
  7. Global Research Centers and Institutions.....II-642 $200  
   Centre for Biologic Nanotechnology (USA).....II-64
Centre for Biological and Environmental Nanotechnology (USA).....II-64
Institute of Bioengineering and Nanotechnology (Singapore).....II-64
1$100
   The Nanobiotechnology Center (USA).....II-65
The Tyndall National Institute (Ireland).....II-65
1$100
  8. Research & Technology Effervescence.....II-667 $700  
   Dendritic NanoTechnologies Develops Novel Priostar™ Dendrimer Technology.....II-66
Scientists Develop Novel DNA Buckyballs for Drug Delivery Applications.....II-66
Nanotechnology Creates Hopes for Artificial Kidneys.....II-66
Chinese Scientists Develop Novel Drug Delivery System.....II-66
1$100
   Scientists Attach Nanograins to Iron Oxide Nanoparticles for Drug Delivery.....II-67
Researchers Employ Nanotubules to Diffuse Cancer Cells.....II-67
Scientists Develop Innovative Nanoparticles for Cancer Treatment.....II-67
1$100
   Nanobiotech Companies Close in on Developing Avian Flu Vaccine.....II-68
Silver Nanoparticles Show Promise Against HIV-1 Virus.....II-68
Nanoparticles Prove Highly Active Against Water Contaminants.....II-68
Nanobiotechnology Offers Major Breakthrough in New HIV Drug Development.....II-68
1$100
   Scientists Develop Innovative Nanoparticles to Treat Tumors.....II-69
Nano-sized Polymers Offer Key Application in Treating Tumor Cells.....II-69
Carbon Nanotubes Hold Promise in Development of Synthetic Muscular Tissues.....II-69
1$100
   Silicon Nanowires Offer Key Solutions to Cancer Detection and Diagnosis.....II-70
Antigen Loaded Nanospheres Induce Immune Response.....II-70
Triton's Nanotechnology Promises Potential Tool against Tumors.....II-70
1$100
   Carbon Nanotubes for Development of Advanced Biosensors.....II-71
Scientists Develop New Technology to Produce Gold and Silver Nanoparticles.....II-71
Scientists Develop Optical Biosensors from Single- Walled Carbon Nanotubes.....II-71
Layer-by-Layer Nanoassembly Method for Nanocapsule Synthesis Gets Underway.....II-71
Nanowires Prove Effective in Viruses Detection.....II-71
1$100
   Nanobiotechnology Enables SARS Test Development.....II-72
1$100
  9. Product Introductions/Developments.....II-732 $200  
   Evident Technologies Introduces Metal Quantum Dot Reagents.....II-73
Abraxis Oncology Launches Novel Abraxane Drug Delivery System.....II-73
Nanophase Introduces Novel Zinc Oxide Nanomaterial.....II-73
ANP Technologies Develops Innovative Biological Detection System.....II-73
1$100
   Acrongenomics Introduces Innovative Cancer Detection Equipment.....II-74
1$100
  10. Recent Industry Activity.....II-757 $700  
   Invitrogen Acquires Quantum Dot Corporation.....II-75
NABsys and Brown University Forge Partnership.....II-75
University of Maryland Forges Partnership with University of Maryland Biotechnology
  Institute.....II-75
ANP Technologies Partners with Cogent Systems.....II-75
NCI forms Strategic Partnership with NSF.....II-75
1$100
   Debiopharm and Nanocarrier Ink Pact to Develop Platinum Anti Cancer Product.....II-76
Capsulution and Ebara Sign Manufacturing Agreement for Nano-capsules.....II-76
Invitrogen Licenses Nanoclusters Technology from Georgia Tech Research.....II-76
Dendritic NanoTechnologies, Starpharma, and Dow Ink Pact.....II-76
Dendritic Nanotechnologies Inks Collaboration Pact with NCL.....II-76
1$100
   Flamel Terminates Licensing Agreement with Biovail.....II-77
MFIC Corporation and University of Massachusetts Sign Collaboration Pact.....II-77
TAP Delivers Notice to Terminate Licensing Agreement with Flamel.....II-77
Nanophase Inks Pact with Competitive Technologies.....II-77
Infectech Changes Name to Nanologix.....II-77
1$100
   Arrowhead Establishes Nanobiotechnology Company.....II-78
NCI Grants Funds to Establish Centers of Cancer Nanotechnology Excellence.....II-78
Capsulution Bags Patents to Develop and Market Nano and Microstructures.....II-78
Capsulution Receives Patent for Production of Novel Nano and Micro-Capsules.....II-78
1$100
   Carbon Nanotechnologies Wins 30 Patents for Small-diameter Carbon Nanotubes.....II-79
Adnavance Technologies Receives Funding for M-DNA Technology.....II-79
Angstrom Medica Wins FDA Approval for Nanoss™ Bone Void Filler.....II-79
Carbon Nanotechnologies and C Sixty Merge.....II-79
Capsulution and Nanosolutions to Join Forces.....II-79
1$100
   UK Institutions Forge Partnership to Develop Novel Therapy for Cancer.....II-80
Triton and XOMA Sign Licensing Agreement.....II-80
BioTrove Receives $11.1Million Funding to Develop Nanobiotechnology Products.....II-80
Alnis Secures $2.71 Million Funding from NCI.....II-80
Invitrogen Acquires Genicon's RLS Technology.....II-80
1$100
   C Sixty Inks License, Option and Supply Agreement with Merck......II-81
Alnis Wins Health Contract Award from NCI.....II-81
1$100
  11. Focus on Select Global Players.....II-826 $600  
   Alnis Biosciences, Inc. (USA).....II-82
American Pharmaceutical Partners, Inc. (USA).....II-82
Biosante Phosphate Pharmaceuticals, Inc. (USA).....II-82
Capsulution NanoScience AG (Germany).....II-82
1$100
   Carbon Nanotechnologies, Inc. (USA).....II-83
C Sixty, Inc. (USA).....II-83
Dendritic Nanotechnologies, Inc. (USA).....II-83
Dendritech, Inc. (USA).....II-83
1$100
   Elan Pharmaceuticals (USA).....II-84
Flamel Technologies, Inc. (France).....II-84
iMedd, Inc. (USA).....II-84
Nanospectra Biosciences, Inc. (USA).....II-84
Nanophase Technologies Corporation (USA).....II-84
1$100
   Nano-C, Inc. (USA).....II-85
Nanocyl SA (Belgium).....II-85
Nanolab Systems Ltd. (Finland).....II-85
Nanosphere, Inc. (USA).....II-85
1$100
   Nanotherapeutics, Inc. (USA).....II-86
Nanosys, Inc. (USA).....II-86
PSiVida Ltd (Australia).....II-86
Quantum Dot Corp. (USA).....II-86
1$100
   Starpharma Holdings Ltd. (Australia).....II-87
Sigma Aldrich Company (USA).....II-87
Triton Biosystems, Inc (USA).....II-87
1$100
  12. Global Market Perspective.....II-88   
   Table 4: World Recent Past, Current & Future Analysis for Nanobiotechnology by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-88

Table 5: World 10-Year Perspective for Nanobiotechnology by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart).....II-88
1$350
   Table 6: World Recent Past, Current & Future Analysis for Nanomaterials by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-89

Table 7: World 10-Year Perspective for Nanomaterials by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart).....II-89
1$350
   Table 8: World Recent Past, Current & Future Analysis for Solid Inorganic Nanoparticles by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010(includes corresponding Graph/Chart).....II-90

Table 9: World 10-Year Perspective for Solid Inorganic Nanoparticles by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart).....II-90
1$350
   Table 10: World Recent Past, Current & Future Analysis for Nanocomposites by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-91

Table 11: World 10-Year Perspective for Nanocomposites by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart).....II-91
1$350
   Table 12: World Recent Past, Current & Future Analysis for Nanostructured Materials & Membranes by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-92

Table 13: World 10-Year Perspective for Nanostructured Materials & Membranes by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart).....II-92
1$350
   Table 14: World Recent Past, Current & Future Analysis for Nanotubes and Fullerenes by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-93

Table 15: World 10-Year Perspective for Nanotubes and Fullerenes by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart).....II-93
1$350
   Table 16: World Recent Past, Current & Future Analysis for Other Nanomaterials by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-94

Table 17: World 10-Year Perspective for Other Nanomaterials by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart).....II-94
1$350
   Table 18: World Recent Past, Current & Future Analysis for Nanodevices/Tools by Geographic Region – USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-95

Table 19: World 10-Year Perspective for Nanodevices/Tools by Geographic Region – Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart).....II-95
1$350
III. MARKET41$1950
  1. The United States.....III-118 $1125  
   A. Market Analysis.....III-1
Outlook.....III-1
Industry Overview.....III-1
Public Sector Funding.....III-1
1$75
   Major Nanobiotechnology Institutions and Centers.....III-2
The Nanobiotechnology Center (NBTC).....III-2
1$75
   Principal NBTC Partners.....III-3
Centre for Biologic Nanotechnology (CBN).....III-3
Centre for Biological and Environmental Nanotechnology (CBEN).....III-3
1$75
   Regulatory Environment.....III-4
Technological Developments.....III-4
3$225
   Product Introductions/Developments.....III-71$75
   Strategic Corporate Developments.....III-84$300
   Key Players.....III-125$375
   B. Market Analytics.....III-17
Table 20: US Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-17
1$200
   Table 21: US 10-Year Perspective for Nanobiotechnology by Technology Segment –Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart).....III-18
1$200
  2. Japan.....III-193 $325  
   A. Market Analysis.....III-19
Outlook.....III-19
Public Sector Funding.....III-19
Technological Development.....III-19
1$75
   B. Market Analytics.....III-20
Table 22: Japanese Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-20
1$200
   Table 23: Japanese 10-Year Perspective for Nanobiotechnology by Technology Segment – Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/ Tools for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart).....III-21
1$200
  3. Europe.....III-2213 $975  
   A. Market Analysis.....III-22
Outlook.....III-22
Market Overview.....III-22
European Union Banks Heavily on Nanobiotechnology.....III-22
2$150
   Nano2Life Network III-23 Major Nanobiotechnology Networks in Europe.....III-24
Public Sector Funding.....III-24
1$75
   Table 24: European Nanobiotechnology Market (2003 & 2004): Percentage Breakdown of Public Sector Funding by Leading Region/Country - European Commission, Germany, France, UK, and Others (includes corresponding Graph/Chart).....III-25
Regulatory Environment.....III-25
Registration for Novel Nanobiotech Drugs Pose Major Bottlenecks.....III-25
1$200
   Focus on Select Markets.....III-26
Germany.....III-26
France.....III-26
United Kingdom.....III-26
1$75
   Rest of Europe.....III-27
Ireland.....III-27
Market Overview.....III-27
1$75
   Key Research Institutions/Centers in Nanobiotechnology.....III-28
The Tyndall National Institute.....III-28
The Centre for Research on Adaptive Nanostructures and NanoDevices.....III-28
The National Centre for Sensor Research.....III-28
The Sami Nasr Institute for Advanced Materials Science.....III-28
1$75
   Technological Developments.....III-29
Strategic Corporate Developments.....III-29
2$150
   Key Players.....III-312$150
   B. Market Analytics.....III-33
Table 25: European Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-33
1$200
   Table 26: European 10-Year Perspective for Nanobiotechnology by Technology Segment – Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/ Tools for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart).....III-34
1$200
  4. Rest of World.....III-357 $1025  
   A. Market Analysis.....III-35
Outlook.....III-35
Public Sector Funding.....III-35
1$75
   Table 27: Nanobiotechnology Market in Rest of World (2004): Percentage Breakdown of Public Sector Funding by Leading Country – South Korea, Taiwan, China, Australia, Canada, and Others (includes corresponding Graph/Chart).....III-36
Focus on Select Markets.....III-36
Australia.....III-36
Market Overview.....III-36
Innovative Drug Delivery – A Key Focus Area for Major Australian
  Companies.....III-36
1$200
   Nanobiotechnology Offers Major Breakthrough in HIV Drug Development.....III-37
Major Institution.....III-37
1$75
   India.....III-38
Market Overview.....III-38
Korea.....III-38
Market Overview.....III-38
1$75
   Table 28: Korean Nanobiotechnology Market (2003 & 2004): Funding in US$ Million by Major Organization Type - University Centers, Public Research Institution, and Companies (includes corresponding Graph/Chart).....III-39
Key Players.....III-39
1$200
   B. Market Analytics.....III-40
Table 29: Rest of World Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment – Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-40
1$200
   Table 30: Rest of World 10-Year Perspective for Nanobiotechnology by Technology Segment – Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools for Years 2000, 2005 & 2010. (includes corresponding Graph/Chart).....III-411$200
IV. COMPETITIVE LANDSCAPE170$995
  
Total Companies Profiled: 91 (including Divisions/Subsidiaries - 95)

Region/Country                 Players

The United States                 66
Canada                             5
Japan                              2
Europe                            16
     France                        2
     Germany                       4
     The United Kingdom            2
     Italy                         1
     Rest of Europe                7
Asia-Pacific (Excluding Japan)     5
middle East                        1
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2008, Global Industry Analysts, Inc., USA.